URGN UroGen Pharma Ltd

Price (delayed)

$41.63

Market cap

$2.03B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.97

Enterprise value

$2.15B

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 34

UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel reverse-thermal hydrogel, a ...

Highlights
The gross profit has surged by 105% year-on-year and by 36% since the previous quarter
The revenue has soared by 100% YoY and by 34% from the previous quarter
URGN's debt has surged by 56% year-on-year
UroGen Pharma's equity has decreased by 42% YoY and by 7% from the previous quarter

Key stats

What are the main financial stats of URGN

URGN stock price

How has the UroGen Pharma stock price performed over time
Intraday
-2.64%
1 week
-4.28%
1 month
-11.16%
1 year
132.83%
YTD
77.75%
QTD
13.13%

Financial performance

How have UroGen Pharma's revenue and profit performed over time
Revenue
$188.73M
Gross profit
$171.46M
Operating income
-$66.65M
Net income
-$97.64M
Gross margin
90.8%
Net margin
-51.7%
The gross profit has surged by 105% year-on-year and by 36% since the previous quarter
The revenue has soared by 100% YoY and by 34% from the previous quarter
The operating margin has soared by 73% year-on-year and by 54% since the previous quarter
URGN's net margin has surged by 69% year-on-year and by 45% since the previous quarter

Price vs fundamentals

How does URGN's price correlate with its fundamentals

Growth

What is UroGen Pharma's growth rate over time

Valuation

What is UroGen Pharma stock price valuation
P/E
N/A
P/B
N/A
P/S
11.11
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
11.39
The company's EPS rose by 40% YoY and by 28% QoQ
UroGen Pharma's equity has decreased by 42% YoY and by 7% from the previous quarter
The revenue has soared by 100% YoY and by 34% from the previous quarter
The price to sales (P/S) is 90% higher than the 5-year quarterly average of 6.0 and 25% higher than the last 4 quarters average of 9.1

Efficiency

How efficient is UroGen Pharma business performance
The company's return on sales has surged by 70% YoY and by 50% QoQ
URGN's return on invested capital is up by 44% year-on-year and by 41% since the previous quarter
The ROA has increased by 30% from the previous quarter and by 26% YoY

Dividends

What is URGN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for URGN.

Financial health

How did UroGen Pharma financials performed over time
UroGen Pharma's total assets is 34% lower than its total liabilities
The total liabilities is up by 27% year-on-year
UroGen Pharma's total assets has increased by 21% YoY
URGN's debt has surged by 56% year-on-year
UroGen Pharma's equity has decreased by 42% YoY and by 7% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.